Target Explorer
Search proteins and antigens by modality, status and hallmark
Filter small molecules, antibodies, ADCs, bispecifics, cell therapies and radioligands. Every row links to its pathway and the episode that explains it.
Oncology reference and training
Learn the pathway. See the drug. Check the source.
Ten cancer-signaling pathways, sixteen narrated hallmark explainers and over a hundred drug targets and antigens, linked to each other and to the papers and FDA notices behind them.
10signaling pathways mapped across initiation, growth and metastasis
16hallmark explainer episodes with scripts and end-card references
102drug targets and antigens with modality and US status
Nov 2026last review of FDA approval status
Three connected tools
One target, three views
Video Library
Two-to-three-minute explainers, one hallmark at a time
Each episode puts one pathway element per scene and ends with full references.
Atlas
Matrix, stage map and crosstalk network
See which pathways drive initiation, growth and metastasis, and how they rewire each other.
Follow one thread
From mutation to medicine in four clicks
KRAS G12C locks a molecular switch in the "on" state. The Atlas places it in RTK/RAS/MAPK, Episode 02 explains the relay, and the Target Explorer lists sotorasib and adagrasib with their indications and sources.
- TargetKRAS G12C
- PathwayRTK / RAS / MAPK
- Episode02 · Stuck on "Go"
- DrugsSotorasib, adagrasib
- SourceSanchez-Vega 2018; Simanshu 2017; FDA
Who it is for
Built for teams that need to get the biology right
Training and onboarding
Pharma and biotech L&D, medical science liaisons, clinical operations and new hires. Assign episodes, track completion and keep a shared vocabulary for every pathway and modality.
R&D and business development
A fast first look at the target and antigen landscape: what is approved, what is investigational, and which modality got there first.
Universities and courses
Lecture-ready explainers with complete citations, for cancer biology, pharmacology and drug-development courses.
Start with two free episodes and the full Atlas overview.
Upgrade when you need every episode, the complete target matrix and exports.
Atlas
Ten pathways, three stages, one network
A practical canonical set of cancer-signaling pathways. Pathways act in more than one stage, and their roles depend on tissue context.
| Pathway | Class | Driver genes | Therapies | Open |
|---|
Video Library
Inside Cancer: the pathways that drive tumors
Sixteen episodes organized around the Hallmarks of Cancer. Every episode has a "Where drugs strike" scene and a reference end card.
Target Explorer
Drug targets and antigens
Proteins and antigens mapped to pathway position, modality, example agents and US status. Approval status reflects FDA as of November 2026 and may differ by country.
Short link: pathwaytotarget.com · search directly with pathwaytotarget.com/KRAS
| Modality | Example agents |
|---|
No targets match
Try a broader term, or clear the filters.
Plans
Free to learn. Paid to go deeper.
Learner
$0
For students and curious professionals.
- Full Atlas: matrix, stage map, network
- Episodes 00 and 01, full scripts and references
- First 20 rows of the Target Explorer
Most popular
Professional
$19/ month
For scientists, MSLs and consultants.
- All 16 episodes and new releases
- Complete Target Explorer and CSV export
- Citation export for every episode
- Monthly drug-approval updates
Team
$39/ seat / month
For training programs, 5 seats minimum.
- Everything in Professional
- Assignments, quizzes and completion certificates
- LMS export (SCORM) and admin dashboard
Enterprise
Custom
For pharma, biotech and institutions.
- Custom pathway and mechanism-of-action videos
- Data licensing and API access
- Private branding and single sign-on
Questions
Is this medical advice?
No. The content is for education and research reference only. It does not recommend treatment and is not a substitute for prescribing information or clinical judgment.
How current is the drug information?
US approval status is checked against FDA approval notices and labels every month. Each row shows the status and the review date.
Are the videos sponsored by drug companies?
No. Episodes are independent and mention drugs by generic name as examples of each target class.
Can I cancel anytime?
Yes. Monthly plans cancel at the end of the billing period; annual plans can be refunded in full within 14 days of the first payment. See the Refund and Cancellation Policy.
About
Editorial standards
How the content is built
Every episode script is drawn from peer-reviewed review articles, including the Hallmarks of Cancer framework of Hanahan and Weinberg, and every end card lists full citations with DOIs. Drug status comes from FDA approval notifications and labels, with the review date shown on each record.
Review and updates
Scripts are reviewed by subject-matter experts before release. Drug-approval status is rechecked monthly, and corrections are logged with a date.
Independence
Content is independent of drug manufacturers. Brand and product names belong to their owners and are used only to identify approved agents.